We believe the patient voice should be at the heart of care. Through open communication and informed discussion, clinicians and patients can work together to make informed treatment decisions, tailored to individual needs. In recognition of Movember, we are delighted to partner with the brightest minds in prostate cancer treatment and care: Dr Alison Birtle, Consultant Clinical Oncologist at The Rosemere Cancer Centre, Preston, and expert patient advocates Dr Erik Briers and Guenther Carl, members of Europa Uomo EU to explore the power of shared decision-making in driving personalised care for people living with prostate cancer. By focusing on what matters most to each patient, we can collectively redefine care, foster stronger patient-clinician relationships, and bring more timely, targeted and effective treatments to those living with prostate cancer. Read the article: https://brnw.ch/21wP19r #ProstateCancer #SharedDecisionMaking #Movember
About us
At Johnson & Johnson Innovative Medicine, we are leading where medicine is going. The experiences of patients around the world inform and inspire our science-based innovations, which continue to change and save lives. Applying rigorous science with compassion, we confidently address the most complex diseases of our time and develop the potential medicines of tomorrow. We are continuously working to develop treatments, aspiring to find cures, pioneering the path from lab to life, and championing patients every step of the way. Visit our Johnson & Johnson Innovative Medicine EMEA website here: https://innovativemedicine.jnj.com/emea/
- Website
-
https://innovativemedicine.jnj.com/emea/?utm_source=linkedin&utm_medium=organic&utm_campaign=bio
External link for J&J Innovative Medicine Europe, Middle East & Africa (EMEA)
- Industry
- Pharmaceutical Manufacturing
- Company size
- 10,001+ employees
- Headquarters
- Beerse
- Type
- Public Company
Locations
-
Primary
Get directions
Turnhoutseweg, 30
Beerse, BE
Employees at J&J Innovative Medicine Europe, Middle East & Africa (EMEA)
Updates
-
Closing the access gap between communities and care is a priority for us at Johnson & Johnson. Medicines can only help people if people can get access to them. We’re proud to be recognised for more than a decade as a top five company in the Access to Medicine Index Report. We partner with healthcare providers, governments, regulators and payers to accelerate access to our medicines and technology for people who need them most. Embedding health equity is central to everything we do. Read more: https://lnkd.in/e9U5Ukjq #ATMI24 #AccessToMedicine #HealthEquity #GlobalHealth
-
-
Our ongoing commitment to the lung cancer community is unwavering, but moments like Lung Cancer Awareness Month (LCAM) help to reaffirm that commitment and recognise those that have been touched by lung cancer. Carolyn Sousa,?EMEA?Regional Commercial Strategy Lead, Oncology, Solid Tumours, shares her?personal experiences?and views on why shared decision-making at the time of?cancer diagnosis is so?crucial in empowering patients to be active collaborators in their care decisions. #lungcancer #LungCancerAwarenessMonth
November is Lung Cancer Awareness Month (LCAM) – a moment where we come together to encourage conversations on lung cancer to raise awareness, recognise the latest medical treatment innovations and stand united in solidarity with the millions of people that it impacts. For me, LCAM is deeply personal. Having lost my father-in-law to the disease, I’m well aware of the immense physical and emotional toll it takes on everyone involved in the journey. LCAM also represents a time to champion the work of patient advocacy groups in helping people feel supported and heard through these profoundly challenging times. In my article, I delve into the importance of advocacy groups in amplifying the voice of those affected by lung cancer, and how I’m proud to be part of a company that puts that voice first. #LungCancerAwarenessMonth #LungCancer #MyCompany
-
We’re committed to transforming pulmonary arterial hypertension (PAH) into a long-term manageable condition. PH Human is a platform to support people living with PAH, and their loved ones, through access to helpful resources and testimonials from other people living with the condition. Learn more on JWM: https://brnw.ch/21wOYIn? #PulmonaryHypertension #PHAwarenessMonth
-
-
How can we tackle key challenges in Central Europe and Baltics? By closing the gap! Find out more in our latest Transforming Health episode, where Tuba Albayrak and Laura Saar talk about health disparities between East and West, and how improving data collection will fundamentally transform the lives of our patients. You can listen to the episode here: https://spoti.fi/4fNIbhV or on your preferred streaming platform. #TransformingHealthcare #PatientCare #FutureOfHealthcare
-
Prostate cancer remains a significant global health challenge, and people living with this disease continue to experience unmet needs that affect their quality of life. Europa Uomo EU's EUPROMS 2.0 study on the relationship between shared decision-making and quality of life for people facing prostate cancer shines a light on the vital role of collaboration between healthcare providers and patients in promoting better health outcomes that focus on holistic care. Learn more about the impact of shared decision-making on patient experiences and quality of life: https://brnw.ch/21wOPYh #ProstateCancer #Movember
-
EFPIA - European Federation of Pharmaceutical Industries and Associations has published new research providing an in-depth analysis on the economic and societal footprint of the pharmaceutical industry in Europe. The data underscores how the pharmaceutical sector is a key pillar of the EU economy. Did you know? ? It is x3 as productive as the European economy ? It contributes a total of €311 billion to the EU economy ? It supports 2.3 million jobs in the EU Europe has a strong track record of recognising and responding to the need for investment in healthcare. But in many countries the principle is now threatened by short-term financial thinking, ageing populations and a projected increase in the burden of chronic illness. At the same time, there is increased competition from China and the US, and Europe risks falling behind. We must reboot our industry’s potential and prioritise its growth potential. Continued investment is crucial to improve societal outcomes, build resilient systems and enable patient access to innovative new therapies, whilst boosting economic productivity. At Johnson and Johnson, we innovate with purpose to lead where medicine is going and push boundaries and deliver groundbreaking treatments for those who need it most. We see health as an investment, not a cost. For more information, the full report can be accessed here: https://brnw.ch/21wONVd #ValueOfHealth #EFPIA #EconomicGrowth
Economic Footprint of the Pharmaceutical Industry in Europe
efpia.eu
-
This World Prematurity Day, we proudly stand with EFCNI to raise awareness around the critical needs of parents and children most vulnerable to the impacts of insufficient maternal foetal care. ? High-quality support and timely access to care is a crucial right and can go a long way in transforming outcomes for people who are affected.? ? #WorldPrematurityDay2024
Today, on ?????????? ?????????????????????? ??????, we join a global community of advocates, families, and healthcare professionals to call for equitable, high-quality care for every preterm baby. With over 13 million babies born too soon each year, our theme—“Access to quality care everywhere!”—aims to inspire action worldwide. ???? We are proud of the incredible dedication we see within our community, both online and on the ground. From lighting landmarks in purple to hosting awareness events, each act of advocacy builds a future where preterm babies and their families receive the support they need. Let’s keep the momentum going! ?? #WPD2024 #WorldPrematurityDay #WorldPrematurityDay2024 #WPD #BornTooSoon
-
-
We are looking forward to watching Martin today at the POLITICO Healthcare Summit.
Vice President, Health Economics, Mkt Access & Reimbursement at Janssen, Pharmaceutical Companies of Johnson and Johnson
Going to the POLITICO Healthcare Summit on 19-20 Nov? There are plenty of challenges and opportunities with HTA right now, and I’m looking forward to discussing them on this panel: ???????????? ???????????????????? ???????????????????? – ???????????????????? ?????? ???????????? ???? ???????? ?????????????? ?????? ????????????. I’ll be joining Judith Fernandez from Haute Autorité de Santé, Fran?ois Hou?ez from EURORDIS, Maya Matthews from the European Commission, and Elena Petelos from EUPHA. It’s free to attend online, so do click the link to register and join us as we explore this crucial topic: https://bit.ly/4hy9qPr #HealthTechnologyAssessment #HTA #PatientAccess #HealthcareInnovation #POLITICOHealthcareSummit
Health Care Summit 2024
politico.eu
-
Our last Transforming Health episode for the year is out now and takes us to Central Europe and the Baltics.?? ? Host Laura Ketteringham is joined by Tuba Albayrak, Managing Director, and Laura Saar, Market Access Director, for Central Europe and Baltics, to better understand the unique challenges faced across the 14 diverse countries in this region.?? ? They share what motivates their work every day, from personal experiences navigating the healthcare system to partnering with patient advocates and policy makers on unmet needs in healthcare.? ? You can find the episode here: https://spoti.fi/4fNIbhV or on your preferred streaming platform.?? ? #TransformingHealthcare #PatientCare #FutureOfHealthcare?